Profound Medical Q2 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $2.233M Beat $2.100M Estimate
Portfolio Pulse from Benzinga Newsdesk
Profound Medical (NASDAQ:PROF) reported Q2 2024 GAAP EPS of $(0.28), beating the estimate of $(0.30). Sales were $2.233M, surpassing the $2.100M estimate. This represents a 20% improvement in EPS and a 39.39% increase in sales compared to the same period last year.
August 08, 2024 | 9:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Profound Medical (NASDAQ:PROF) reported better-than-expected Q2 2024 results with GAAP EPS of $(0.28) beating the $(0.30) estimate and sales of $2.233M surpassing the $2.100M estimate. This indicates a 20% improvement in EPS and a 39.39% increase in sales year-over-year.
The better-than-expected earnings and sales figures are likely to positively impact the stock price in the short term. The significant year-over-year improvements in both EPS and sales further strengthen the positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100